Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections
about
Can nanomedicines kill cancer stem cells?Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug deliveryCellular Responses and Tissue Depots for Nanoformulated Antiretroviral TherapyPharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations.Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance.Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapiesOpposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophagesProlonged-acting, multi-targeting gallium nanoparticles potently inhibit growth of both HIV and mycobacteria in co-infected human macrophages.Magnetic resonance imaging of folic acid-coated magnetite nanoparticles reflects tissue biodistribution of long-acting antiretroviral therapyPharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized miceLong-acting slow effective release antiretroviral therapy.Investigational reverse transcriptase inhibitors for the treatment of HIV.Gallium nanoparticles facilitate phagosome maturation and inhibit growth of virulent Mycobacterium tuberculosis in macrophages.The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapyGeneration and Disease Model Relevance of a Manganese Enhanced Magnetic Resonance Imaging-Based NOD/scid-IL-2Rγc(null) Mouse Brain Atlas.Long-acting injectable antiretrovirals for HIV treatment and preventionInvestigational protease inhibitors as antiretroviral therapies.Creation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-ThiacytidineNanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics.Neuronal protection against oxidative insult by polyanhydride nanoparticle-based mitochondria-targeted antioxidant therapy.Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS.Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging.Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugsNanomedicines for dysfunctional macrophage-associated diseases.Development and characterization of a long-acting nanoformulated abacavir prodrugMultimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution.Interview: Nanomedicine and the fight against HIV/AIDS.Nitric oxide-activatable gold nanoparticles for specific targeting and photo-thermal ablation of macrophages.Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals.Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice.Harnessing nanostructured systems for improved treatment and prevention of HIV disease
P2860
Q27022017-B44B6470-67F9-49D0-ACE0-99B1B1F52753Q28081272-C56159FB-772E-4D8B-B704-C0405DF6127FQ28551873-763FC0C0-6145-477B-A97B-C0A104DED5A0Q30603781-4C9A381D-A2AA-4BCB-9B1C-1F6E32DD9167Q34059457-2E520571-0E5C-4F3E-8743-64014DB018FAQ34745586-70AFB3D1-6105-4A37-BDBF-3D4EE50B487CQ34797004-96A81785-C801-4425-BF75-6B611C90E01DQ35016131-814FC774-BBE0-490D-8058-D884E62ED70BQ35153311-F41734AF-50F4-410C-967E-AA9C6026EC8EQ35703450-A454D48E-94A7-4D27-82E4-4C277E762575Q35822619-88CCAB7D-A040-4439-BDD7-BEBF4BA3C8C5Q36262152-6FAF75F3-877D-4C44-AD01-5F92FE4321B2Q36306231-6C86C7D8-C4BB-47EE-B2DF-4382BBA6B445Q36381046-461F1556-865D-4B5F-99DF-9DFD0088CE51Q36505647-18A05865-5BCD-467E-A3DD-8FE2D61B4614Q36914204-49DEBEF5-81A9-4B94-A7F8-C2FDEDAC9FA8Q37272776-5286F7DA-7E87-41D3-B9A7-67DC0B76E104Q37582521-635C49C4-943B-40BB-85F1-28905DC42B85Q37639081-DFD80FBB-24A0-4C92-BD44-ADDF465D277CQ38495022-3A50DD80-C285-484E-8DAB-2516B81DD9A5Q38738244-04267C4F-34E5-474E-9EE3-0EE4CA582CCBQ38761022-83EC42E7-B793-45A4-9682-645D3249CD07Q38787356-84595ADD-27ED-4409-AF5D-F5DF3D5ECCA2Q38992323-1C4C2259-4763-4F1C-8A3C-D5DC31E9048AQ39069052-D51486E8-DEEE-46AA-AB15-D42763943E19Q41280373-21D211EC-F209-43C9-A4B4-C49B8E93E859Q47095093-01D5BEDA-B536-4E36-82BE-D4EF3E419CC2Q48375952-FEEB9059-A18B-46E3-A566-4EA30BC98F45Q49684303-4985F9E7-B8AA-4098-9143-59C2BF3101BCQ54253541-F37291FD-03A8-4EBC-8BE8-875D879DC4F9Q54267469-799B4DF3-99E4-45C6-B684-BC6CB8575101Q56992437-BE42D4EA-79BC-4139-A18F-F04F9D31FCC7
P2860
Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Macrophage folate receptor-tar ...... unodeficiency virus infections
@en
Macrophage folate receptor-tar ...... nodeficiency virus infections.
@nl
type
label
Macrophage folate receptor-tar ...... unodeficiency virus infections
@en
Macrophage folate receptor-tar ...... nodeficiency virus infections.
@nl
prefLabel
Macrophage folate receptor-tar ...... unodeficiency virus infections
@en
Macrophage folate receptor-tar ...... nodeficiency virus infections.
@nl
P2093
P2860
P1476
Macrophage folate receptor-tar ...... unodeficiency virus infections
@en
P2093
Benson J Edagwa
Howard E Gendelman
Joellyn McMillan
Lindsey Kendrick
Nathan Smith
Pavan Puligujja
Ram S Veerubhotla
Shantanu Balkundi
Tatiana Bronich
Tianyuzi Li
P2860
P304
P356
10.1016/J.NANO.2013.05.003
P50
P577
2013-05-13T00:00:00Z